Diagnosis & Screening Trials

 

• STUDY11523
  
  Tomosynthesis Mammographic Imaging Screening Trial (TMIST)
  
  This randomized phase III trial studies digital tomosynthesis mammography and digital mammography in screening patients for breast cancer. Screening for breast cancer with tomosynthesis mammography may be superior to digital mammography for breast cancer screening and may help reduce the need for additional imaging or treatment.
  
  Study Information

  ---

  
  

• STUDY14725
  
  LUNGMAP: A Master Protocol To Evaluate Biomarker Driven Therapies And Immunotherapies In Previously Treated Non Small Cell Lung Cancer (Lung Map Screening Study)
  
  This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
  
  Study Information

  ---

  
  

• STUDY16674
  
  FDG PET to Assess Therapeutic Response in Patients With Bone Dominant Metastatic Breast Cancer, FEATURE
  
  This phase II trial studies how well FDG-PET/CT works in assessing the response of patients with breast cancer that has spread to the bones or mostly to the bones (bone-dominant metastatic breast cancer). Diagnostic procedures, such as FDG-PET/CT, may work better in measuring breast cancer activity before and after treatment compared to other standard imaging tests.
  
  Study Information

  ---

  
  

• STUDY17368
  
  Adequacy for molecular analysis in EBUS TBNA specimens vs. liquid biopsies in patients with NSCLC, aka, \"The Liquid Trial\"
  
  Compare the diagnostic yield for detecting EGFR, ALK, ROS1, BRAF, Kras via next generation sequencing mutations in EBUS-TBNA specimens versus liquid biopsy specimens.
  
  Study Information

  ---

  
  

• STUDY18402
  
  Determination and Validation of Lung EpiCheck®: A Multianalyte Assay for Lung Cancer Prediction
  
  To select a panel of markers, define the algorithm and cut-off value that will differentiate between lung cancer and individuals at high-risk for lung cancer and will allow for the early detection of stage I and II lung cancer tumors in high-risk population To validate the performance of Lung EpiCheck in terms of sensitivity, specificity, NPV and PPV based on screen-detected and enriched stage I and II lung cancer cases and on individuals at high risk for lung cancer that were negative by lung cancer screening.
  
  Study Information

  ---